In order to decrease administrative burden and costs, the Center for Medicare and Medicaid Services has proposed collapsing billing codes for level II-V office visits into a single code that would reimburse in a range between level III and IV. We evaluated the impact that such a change would have on reimbursement for urologists treating Medicare beneficiaries.
INTRODUCTION AND OBJECTIVES:
In order to decrease administrative burden and costs, the Center for Medicare and Medicaid Services has proposed collapsing billing codes for level II-V office visits into a single code that would reimburse in a range between level III and IV. We evaluated the impact that such a change would have on reimbursement for urologists treating Medicare beneficiaries.
METHODS: We identified urologists captured by the publiclyavailable Medicare Provider Payment Database and examined payments for fee-for-service beneficiaries in 2016. For each provider, the database provided demographics, ZIP code of practice, and services and average payments aggregated at service level by CPT codes. Our intervention was changing average payments for CPT 99202-99205 and CPT 99212-99215 to a single value between level III and IV for new (CPT 99203/99204) and established (CPT 99213/ 99214) visits. The main provider-level outcomes were (a) change in payments for office outpatient services and (b) percent change in overall reimbursement. We used bivariate statistics and linear regression models to assess association of provider factors and geography with these outcomes.
RESULTS: We identified 8,865 urologists who received Medicare fee-for-service payments in 2016. (8.3% female; 94.5% M.D.).
Median reimbursement was $175,655 (IQR $85, 916) , and median payments for office visits was $50,651 (IQR $25, 073) . The proposed policy would result in an estimated $16.6 million in annual savings. With the proposed change, median change in reimbursement for outpatient office visits would be -$572 901) . The average % change in overall reimbursement would be -1.9% (SD 7.0) (Figure) . 23% of urologists would have a 5% decrease in reimbursement. Compared to male urologists, female urologists had a significantly greater decrease in reimbursement (-3 Figure 1 demonstrates the distribution of LOS by surgical approach and procedure. Overall, 23% of patients had LOS 1 day with rates ranging from 0% to 44.7% across practices (Figure 1 ). There were no other significant predictors of LOS: demographic, clinical, tumor complexity. Readmission was uniformly low with only 6% of the cohort readmitted within 30 days of hospitalization. Increasing Charlson Comorbidity index (p< 0.01) and prolonged LOS (p[0.04) were associated with readmission.
CONCLUSIONS: Within a large state-wide collaborative, most patients treated with a localized RM 7cm require at least a 2 day admission to the hospital. Only 26% of patients undergoing MIPN and 17% of MIRN patients required 1 day in the hospital, suggesting opportunities to work collaboratively with insurers to set appropriate hospital utilization expectations for this cohort. Establishment of pathways and understanding other variations in care might allow optimization of the in-hospital and post-hospital recovery in this "real world" cohort of patients.
Source of Funding: funding from Blue Cross Blue Shield of Michigan

PD67-07 SUCCESS RATE AND SAFETY OF OFFERING SAME-DAY DISCHARGE FOLLOWING ROBOTIC PROSTATECTOMY
Robert Gerhard, Oscar Martinez, Ronney Abaza*, Dublin, OH INTRODUCTION AND OBJECTIVES: The average length of stay following robotic-assisted radical prostatectomy (RARP) is 24-48hrs and potentially longer on average in community settings. If safe, same day discharge (SDD) following RARP could allow considerable cost savings. The largest previous reports of SDD after RARP include less than 50 highly-selected patients. We report our experience routinely offering SDD after RARP in a community setting and evaluate the safety and cost implications.
METHODS: Beginning September 2016, we adjusted our RARP clinical pathway to allow SDD. This included using ultra-low pneumoperitoneum at 6mmHg, immediate ambulation, immediate diet, and scheduled non-narcotic analgesia with optional oral but no intravenous narcotics. Patients were given the option for SDD without it being mandated. After allowing a period of three months to solidify the protocol, we evaluated our prospective database for the next 500 consecutive patients to determine the success rate and safety of SDD.
RESULTS: Of 500 consecutive RARPs performed in 18 months, 246 patients (49.2%) were discharged the day of surgery with all of the remaining 254 discharged the next day for a mean length of stay of 0.51 days. Characteristics included mean age 62yrs (range, 42-81yrs) and BMI 29.7kg/m 2 (range, 20-53kg/m 2 ). All patients underwent lymphadenectomy with yield of 8.1 nodes (range, 2-24) with OR time of 161min and blood loss of 135mL with no transfusions. Thirty-four patients (6.8%) overall had a Clavien-Dindo grade I-III complication within 90 days of surgery with no grade IV-V complications, of which only 5 required a visit to the emergency department (1%) and only 8 required readmission (1.6%). Among patients discharged on the day of surgery, only one was readmitted (for deep vein thrombosis), and only one presented to the emergency department (for occluded catheter). The estimated charge for overnight postoperative admission at our institution is $2,109, such that the approximate reduction in charges was $518,814 over 18 months ($345,876/yr) with no increase in costs from emergency room visits or readmissions as compared with patients who stayed longer. Among the most recent 200 patients, the rate of SDD improved to 52.5%, and in the most recent 100 patients it improved to 65%.
CONCLUSIONS: Same-day discharge following RARP can be applied safely in a subset of patients with no increase in readmissions or emergency visits and may lead to significant savings in healthcare costs. To our knowledge, this is only large series examining the safety and feasibility of SDD after RARP reported to date. We developed a novel approach to extract both anticipated and actual trial accrual. We apply these previously unavailable data to describe accrual adequacy and identify predictors of poor accrual.
METHODS: Records for all GU cancer clinical trials started since 2005 were extracted from ClinicalTrials.gov. We employed a custom Python web scraper to extract anticipated and actual accrual information and trial characteristics from the ClinicalTrials.gov archives. Logistic regression was used to identify predictors of failing to meet 50% or 85% of anticipated accrual.
RESULTS: A total of 3,976 completed or terminated genitourinary cancer trials were extracted, of which 1,322 unique trials had complete records. Only 42% of trials met their anticipated accrual goals, and 30% enrolled fewer than half of their anticipated patients (Table) . Of trials reported as completed, only 54% reached their accrual goals; 17% failed to reach 50% of anticipated accrual. On logistic regression, prostate (OR 0.64, 95% CI 0.45-0.91) and testicular (OR 0.44, 95% CI 0.18-0.96) trials, as well as trials with sites within and outside the USA (OR 0.55, 95% CI 0.35-0.86) were more likely to accrue > 50% of anticipated patients.
